RNS Number: 7907 I Nuformix PLC 03 April 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1002 I Nuformix PLC 30 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5007 F Nuformix PLC 09 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4951 F Nuformix PLC 09 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Karl spent 12 years as a highly regarded sell-side life sciences research analyst, researching and helping finance companies across the UK, Europe, USA and Canada. Karl graduated from University College Dublin, Ireland in 1988 with a B.Sc. in Pharmacology and gained M.Phil. and Ph.D. degrees from the University of Cambridge where he was funded by a Parke-Davis...
RNS Number: 1165 D Nuformix PLC 14 February 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1152 D Nuformix PLC 14 February 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1011 D Nuformix PLC 14 February 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1006 D Nuformix PLC 14 February 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9732 C Nuformix PLC 13 February 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9725 C Nuformix PLC 13 February 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8166 C Nuformix PLC 12 February 2020 NTR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
·On 30 October 2019 Nuformix received confirmation in writing from NSB of an acceptable solution to resolving the outstanding £2.5 m payment due. ·During face-to-face meetings with NSB senior management in Shanghai on 4 th -8 th November 2019, Nuformix Chairman, Dave Tapolczay, was given further verbal assurances of payment by 15 November 2019.
RNS Number: 1161 C Nuformix PLC 05 February 2020 5 February 2020. Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of Dave Tapolczay as non-executive Chairman of the Nuformix Board of Directors with immediate effect..
RNS Number: 0949 C Nuformix PLC 05 February 2020 5th February 2020. Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs was notified that on the 24 th January 2020, David Tapolczay, Non-Executive Chairman of the Group, sold 650,000 Ordinary Shares in the Group at a...
RNS Number: 0940 C Nuformix PLC 05 February 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9772 A Nuformix PLC 27 January 2020 27 January 2020. Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of John Lidgey from the Nuformix Board of Directors with effect on 31 January 2020. John chaired Levrett plc from...
RNS Number: 9774 A Nuformix PLC 27 January 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Nuformix plc
NFX.L
Nuformix plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    469.47M

Featured Media

Company Profile

Nuformix is a pharmaceutical development company using cocrystal technology, unlocking the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis.

Classification

Market Indices-

Locations

HQ
153 Cambridge Science Park
Milton Road
Cambridge
CB4 0GH
Watchlist